Considering that the publication of your February 2022 compounding risk alert, FDA has become mindful of growing general public interest in the usage of sublingual and oral dosage forms of compounded ketamine for that treatment of psychiatric disorders. FDA understands that the opportunity to acquire these goods by telemedicine platforms https://ketalinic.com/ketamine-r-isomer-s-isomer/